Israeli medical cannabis co to build greenhouses abroad

medical cannabis
medical cannabis

Globus Pharma will invest NIS 4 million to build up to 25 acres of greenhouses overseas.

Israeli medical cannabis company Globus Pharma has signed a binding cooperation agreement with Together (TASE: TGTR), which specializes in growing and producing medical cannabis in Israel and exporting its products to international markets. As part of the agreement, Globus Pharma will build and operate a complex of greenhouses for growing, marketing and exporting up to about 60 tons annually of medical cannabis and its products in an area of up to 25 acres in a foreign country. Under the terms of the agreement, Together will hold 51% of the partnership, and the foreign company, which owns the permits and licenses from the relevant authorities for growing, producing, exporting and marketing cannabis will hold 49% of the partnership. A detailed agreement will be signed within 60 days.

Financing for the project will be undertaken through a loan from the owners of Together with an initial amount of up to NIS 4 million, subject to and according to the stages of the business plan, which will be attached to the detailed agreement.

The companies intend building and operating the greenhouses as soon as possible so that the first crop will be harvested in the first quarter of 2019. For this to happen, the partnership will work to complete building the greenhouses no later than six months after the signing of the detailed agreement. In the first stage, the annual yield of cannabis will be about 15 tons and this will be gradually increased to 60 tons according to marketing and distribution agreements with strategic enterprises.

According to the company's estimates, the price of a gram of medical cannabis today sold to the distributor is about $5 per gram. With this in mind, the operating company estimates that potential revenue in the first stage from activities in the foreign country, in 2019, will amount to $75 million with annual revenue rising to $300 million as production increases.

Master Growers with many years of experience will support the project from its inception and will instruct the projects managers and agricultural staff throughout cultivation including production and processing of produce for sale worldwide.

The project will help the company generate substantial revenue from growing cannabis at the same time as the export activities the company expects when the Israeli government grants permission for exports.

Globus Pharma Founding Partner Nissim Bracha said, "We are realizing the company's business strategy by establishing an international agro-technology company. The agreement to build a major complex of greenhouses in a foreign country lays the infrastructure for creating revenue outside of Israel and without dependence on the government's approval of exports. I am convinced that creating cash flow from abroad will lead to diversifying the company's sources of income."

He added, "It is our intention to manage the operations abroad through our own managers who are familiar with the foreign country while relying on the company's farming experts that have many years of experience in growing, enhancing and harvesting medical cannabis products. We believe that producing cannabis products in countries with climate, cost and labor advantages, available water and land will improve profitability for every gram of medical cannabis sold, while creating major value for the company's shareholders."

Published by Globes [online], Israel business news - www.globes-online.com - on March 19, 2018

© Copyright of Globes Publisher Itonut (1983) Ltd. 2018

medical cannabis
medical cannabis
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018